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Abstract
Background: Tumoral calcinosis is a rare manifestation of extraskeletal calcification, featuring large calcified cystic
masses in the periarticular regions of large joints. In chronic kidney disease (CKD), this disorder is thought to
evolve through a chronically elevated calcium-phosphorus solubility product leading to calcium precipitation in
soft tissue. Treating tumoral calcinosis in these patients involves interventions to lower the calcium-phosphorus
product such as reduction in vitamin D therapy and intensive hemodialysis regimens.
Case Presentation: We report the case of a 54-year old woman with polycystic kidney disease on peritoneal dialysis
with widespread tumoral calcinosis in the context of hypercalcemic tertiary hyperparathyroidism who had been on
long-term alfacalcidol therapy. After withdrawal of the vitamin D analogue and initiation of daily hemodialysis, there
was rapid dissolution of her tumoral calcium deposits with the abrupt onset of parathyroid hormone (PTH)-
independent transient hypercalcemia that resolved once the soft tissue deposits disappeared.
Conclusions: Resorption of soft tissue calcific deposits may result in transient parathyroid hormone (PTH)-independent
hypercalcemia. In CKD patients, this hypercalcemia causes a decrease in the PTH level, distinguishing it from tertiary
hyperparathyroidism, though PTH may not be totally suppressed, the way it is seen in PTH-independent hypercalcemia
in non-CKD patients.
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Background
Chronic kidney disease (CKD) represents a state of
disordered calcium and phosphate regulation that often
leads to calcium salt deposition in soft tissue. This
phenomenon of metastatic calcification may be wide-
spread, involving blood vessels, visceral structures, and
subcutaneous and cutaneous tissues [1]. On rare occa-
sions, periarticular calcifications may grow into tumor-like
masses, a manifestation recognized as tumoral calcinosis
[2]. In CKD, an elevated serum calcium-phosphorus (Ca x
P) product is likely the most important factor in the
pathogenesis of tumoral calcinosis [3]. We present the
case of a 54-year old woman with polycystic kidney dis-
ease on peritoneal dialysis (PD) who developed extensive
tumoral calcinosis in the context of an elevated Ca x P
product, hyperparathyroidism and long-term adminis-
tration of a vitamin D analogue. A reversal of the
factors favoring mineralization (vitamin D therapy and
low phosphate clearance) allowed for dissolution of the
calcium deposits, which we hypothesize caused transi-
ent, severe parathyroid hormone (PTH)-independent
hypercalcemia.
Case Presentation
A 54-year old woman with end-stage renal disease
(ESRD) secondary to polycystic kidney disease who was
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on continuous cycling PD (CCPD) was admitted to
hospital with a polycystic liver infection. Her CCPD pre-
scription had been as follows: six cycles involving a total
dialysate volume of 11,800 mL over 9 h plus one day-
time exchange. All of the dialysate bags consisted of a
Dianeal 1.5 % dextrose solution containing a calcium
concentration of 1.25 mmol/L. A peritoneal equilibration
test performed before hospital admission indicated a 24-
h urine output of 1697 mL and a Kt/V of 2.72. For the
past year, she had complained of progressive pain and
immobility of the hips, with scant soft tissue calcium
deposits seen on x-rays 1 year before admission. In
hospital, she was found to have new small, palpable, and
firm masses around her hips and cervical spine. She had
been taking the vitamin D analogue alfacalcidol for years
at a dose of 1.25 mcg orally daily, and was not on a
phosphate binder. She had elevated serum calcium,
phosphate and PTH levels (Table 1). Her calcitriol level
was low at 26 pmol/L. A whole-body positron emission
tomography-computed tomography (PET-CT) scan with
fluorodeoxyglucose before her hospitalization illus-
trated widespread tumoral calcinosis, mainly around
the large joints. Her alfacalcidol was suspended and
she was put on a low-calcium and -phosphate diet
before being admitted to hospital for treatment of her
infected liver cysts.
Two months after the first PET-CT scan, a repeat
PET-CT scan while in-hospital indicated progression of
her tumoral calcinosis (Fig. 1a). For that reason, she was
switched from PD to daily hemodialysis (HD). Her HD
prescription involved 4-h sessions at a maximum blood
pump speed with the following dialysate: sodium
138 mmol/L, potassium 4 mmol/L, calcium 1.25 mmol/
L, and bicarbonate 28 mmol/L. Follow-up PET-CT scans
one and 2 months later demonstrated significant
improvement in her tumoral calcinosis (Fig. 1b, c) ac-
companied by a marked rise in serum calcium and a
precipitous decrease in her chronically elevated PTH
(Table 1). She was continued on daily HD after discharge
from hospital following a 2-month admission. Two
months later, these biochemical changes reversed with
resolution of her tumoral calcinosis, as evidenced by the
disappearance of the calcified masses on palpation and
on PET-CT (Fig. 1d). She was then maintained on HD
five times per week as she awaited an upcoming kidney
transplant.
Conclusions
CKD patients are predisposed to extraskeletal calcifica-
tion because of an elevated Ca x P product [4]. In renal
failure, phosphate excretion and vitamin D activation are
impaired, causing hyperparathyroidism, which drives
calcium release from bone [1]. Calcinosis often occurs,
however, in the absence of hyperparathyroidism [2, 5],
an observation that highlights the importance of PTH-
independent ectopic mineralization-promoting factors in
the generation of an elevated Ca x P product. Such
factors that were present in this case included chronic
hyperphosphatemia, long-term vitamin D analogue
use, and possibly longstanding PD since residual renal
function is known to decrease with time, occasionally with
an insufficient compensatory increase in peritoneal phos-
phate clearance, especially in anuric patients [6].
Massive periarticular calcification, known as tumoral
calcinosis, is a rare manifestation of extraskeletal calcifi-
cation in CKD [2]. The mainstay of treatment involves
measures to lower the Ca x P product [1]. In this case, a
diet low in phosphate and calcium was administered and
the vitamin D analogue was suspended, albeit without
success. The switch from PD to daily HD [4] was, how-
ever, effective in treating the tumoral calcinosis.
It appeared that resolution of the patient’s soft tis-
sue calcifications provoked transient but severe hyper-
calcemia. In CKD, the development of hypercalcemia
is oftentimes the result of chronic vitamin D therapy
with calcium-based phosphate binders. The patient’s
increasing calcium level on HD occurred, however,
after having stopped alfacalcidol. Prolonged stimula-
tion of the parathyroid gland leading to autonomous
PTH hypersecretion (tertiary hyperparathyroidism) is
Table 1 Trend in the patient’s calcium, phosphate, and PTH levels before and after cessation of alfacalcidol and switching to daily















2.5 (10.1) 2.7 (11) 3.4 (14)b 2.2 (8.8) 2.1–2.6 (8.4–10.4)
Phosphate, mmol/L (mg/dL) 1.5 (4.7) 2.0 (6.3) 1.3 (4.1) 1.4 (4.3) 0.8–1.5 (2.5–4.6)
Ca x P product,
mmol2/L2 (mg2/dL2)
3.9 (48) 5.6 (69) 4.4 (55) 3.1 (38) c
PTH, ng/L (pg/mL) 1062 (1062) 332 (332) 84 (84) 158 (158) 7–37 (7–37)
aThese total calcium levels have been corrected for the serum albumin concentration
bThe pre-discharge ionized calcium was also found to be elevated
cProfessional guidelines have recommended a Ca x P product target of less than 4.4 mmol2/L2 (55 mg2/dL2) in stages 3 to 5 CKD [11]
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another cause of hypercalcemia among CKD patients
[7]. Because the PTH in this case was “inappropriately
high” for the severe hypercalcemia, tertiary hyperparathyr-
oidism was considered in the differential diagnosis. How-
ever, a review of her chronic trends in PTH clearly
showed that the calcium rise was acute and that the PTH
of 84 ng/L was relatively “suppressed” in the context of
pre-existing advanced parathyroid hyperplasia. A low
PTH (i.e. < 100 ng/L [8]) in combination with hypercalce-
mia also prompted consideration of adynamic, or low-
turnover, bone disease [9] although this entity too did not
fit with the prior chronically elevated PTH levels and the
acuity of the calcium and PTH changes.
Given the sudden PTH and vitamin D independence (fall
in PTH and low calcitriol, respectively) of the
hypercalcemia coinciding with the disappearance of the
calcific masses clinically and radiographically, it was
thought to be explained by exogenous calcium release from
resorption of her tumoral calcinosis. Daily HD produced a
drop in the Ca x P product, allowing for dissolution of the
calcific lesions, causing soft tissue release of calcium into
the intravascular compartment and hence hypercalcemia.
This hypercalcemia caused relative PTH suppression in-
stead of total suppression as would be expected in non-
PTH mediated hypercalcemia outside of renal failure. Once
the soft tissue deposits disappeared, the hypercalcemia and
relative PTH suppression resolved, which was observed at
2 months following discharge from hospital. This
phenomenon of tumoral calcinosis treatment possibly in-
ducing hypercalcemia has been scarcely reported in the lit-
erature [2, 5, 10]. This case emphasizes the importance of
an extensive review of the calcitropic hormone and mineral
levels over time to assist with the interpretation of any ap-
parent worsening of hypercalcemia in CKD. Additionally,
this serves as a reminder that not all PTH-independent
hypercalcemia necessarily requires the appearance of fully
suppressed PTH levels, particularly in the context of
CKD-associated chronic hyperparathyroidism.
Tumoral calcinosis is an unusual form of soft tissue
calcification. When associated with CKD, measures
should be taken towards lowering the Ca x P product
and reducing the contributors to mineralization. As tu-
moral calcinosis resolves, release of soft tissue calcium
into the general circulation may cause severe, relative
PTH-independent hypercalcemia that is transient and
may be observed without apparent harm to the patient,
as was demonstrated in this case.
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